NovoCure Ltd (MEX:NVCR)
MXN 275.39 0 (0%) Market Cap: 41.40 Bil Enterprise Value: 36.48 Bil PE Ratio: 0 PB Ratio: 6.44 GF Score: 63/100

Novocure Ltd LUNAR Phase 3 Clinical Trial Presentation Transcript

Jun 06, 2023 / 07:00PM GMT
Release Date Price: MXN960 (-28.39%)
William F. Doyle
NovoCure Limited - Executive Chairman

Presentation
Jun 06, 2023 / 07:00PM GMT

=====================
Corporate Participants
=====================
* Ashley Cordova
NovoCure Limited - CFO
* Pritesh Shah
NovoCure Limited - Chief Growth Officer
* William F. Doyle
NovoCure Limited - Executive Chairman

=====================
Conference Call Participants
=====================
* Emily Claudia Bodnar
H.C. Wainwright & Co, LLC, Research Division - VP & Senior Healthcare Analyst
* Jason M. Bednar
Piper Sandler & Co., Research Division - Director & Senior Research Analyst
* Lawrence H. Biegelsen
Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst
* Na Sun
JPMorgan Chase & Co, Research Division - Analyst
* Corey Langer
* Ticiana Leal

=====================
-

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot